We have an updated report [Version - 2023] available. Kindly sign up to get the sample of the report.
all report title image
  • Published In : Aug 2020
  • Code : CMI1271
  • Pages : 188
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical
Ingographics Image

Immuno-oncology is the study and development of treatments that take advantage of the body’s immune system to fight cancer. As immune system is a complex network of organs, cells and molecules that protect the body from foreign substances that cause infection. In addition to finding and destroying foreign substances, the immune system can also locate and attack abnormal cells. Immuno-oncology uses novel immunotherapies that boost the immune system of patients. These therapies target the immune system of the body instead of the tumors and enable the immune system to recognize and target cancer cells. Immuno-oncology does not affect the functioning of healthy cells as opposed to conventional therapies such as chemotherapy and radiation therapy. Long term response can be generated with the help of these therapies as they provide long-lasting memory to the immune system. Immune system adapts to the cancer over time and provides long term response to the cancer. Immuno-Oncology therapy work against a wide variety of cancer, which include non-small cell lung cancer, acute myeloid leukemia, lymphoma, multiple myeloma, breast cancer, and others.

 Market Dynamics

Increasing number of inorganic strategies such as product approval by the key market players is expected to drive the global immuno-oncology drugs market over the forecast period. For instance, in December 2020, Blueprint Medicines Corporation, a biotech company, announced that they had received an approval from the U.S. Food and Drugs Administration for GAVRETO (pralsetinib) for the treatment of patients with advanced or metastatic RET-mutant and RET fusion-positive thyroid cancer. GAVRETO is a once-daily oral precision therapy designed to potently and selectively target RET alterations that drive multiple tumor types.

Key features of the study:

  • This report provides an in-depth analysis of the global immuno-oncology drugs market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global immuno-oncology drugs market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include AbbVie Inc., AstraZeneca, Bristol-Myers Squibb Company, Dendreon Pharmaceuticals LLC., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi, Ferring B.V., Enzo Biochem Inc., Celldex Therapeutics, Atara Biotherapeutics, Inc., Apexigen, BioNTech SE, Blueprint Medicines Corporation, Regeneron Pharmaceuticals Inc., CytomX Therapeutics, Inc., Agenus Inc., Betta Pharmaceuticals Co., Ltd., CStone Pharmaceuticals, Amgen Inc., MediMergent, LLC, Gilead Sciences, Inc., and ONKO-INNATE
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global Immuno-oncology drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global immuno-oncology drugs market

Detailed Segmentation:

  • Global Immuno-oncology Drugs Market, By Treatment Type:
    • Immune Checkpoint Inhibitors
      • PD-1
      • PD-L1
      • CTLA-4
    • Immune System Modulators
    • Cancer Vaccines
    • Oncolytic Virus
    • Others
  • Global Immuno-oncology Drugs Market, By Disease Type:
    • Melanoma
    • Lung Cancer
    • Blood Cancer
    • Renal Cell Carcinoma
    • Prostate Cancer
    • Bladder Cancer
    • Others (Breast Cancer, Thyroid Cancer, etc.)
  • Global Immuno-oncology Drugs Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Immuno-oncology Drugs Market, By Region:
    • North America
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Country
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • AbbVie Inc.*
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • AstraZeneca
    • Bristol-Myers Squibb Company
    • Dendreon Pharmaceuticals LLC.
    • Hoffmann-La Roche Ltd.
    • Merck & Co., Inc.
    • Novartis AG
    • Pfizer Inc.
    • Sanofi
    • Ferring B.V.
    • Enzo Biochem Inc.
    • Celldex Therapeutics
    • Atara Biotherapeutics, Inc.
    • Apexigen
    • BioNTech SE
    • Blueprint Medicines Corporation
    • Regeneron Pharmaceuticals Inc.
    • CytomX Therapeutics, Inc.
    • Agenus Inc.
    • Betta Pharmaceuticals Co., Ltd.
    • CStone Pharmaceuticals
    • Amgen Inc.
    • MediMergent, LLC,
    • Gilead Sciences, Inc.
    • ONKO-INNATE

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snapshot, By Treatment Type
      • Market Snapshot, By Disease Type
      • Market Snapshot, By Distribution Channel
      • Market Snapshot, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Market Trends
    • Pipeline Analysis
    • Acquisitions and Partnerships Scenario
    • Regulatory Scenario
    • Key Developments
    • COVID-19 Impact Analysis
  4. Global Immuno-oncology Drugs Market - Impact of Coronavirus (Covid-19) Pandemic
    • Overall Impact
    • Government Initiatives
    • COVID-19 Impact on the market
  5. Global Immuno-oncology Drugs Market, By Treatment Type, 2017 – 2030, (US$ Million)
    • Overview
      • Market Share Analysis, 2022 and 2030 (%)
      • Y-o-Y Growth Analysis, 2017 – 2030
      • Segment Trends
    • Immune Checkpoint Inhibitors
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
        • PD-1
        • PD-L1
        • CTLA-4
    • Immune System Modulators
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
    • Cancer Vaccines
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
    • Oncolytic Virus
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
    • Others
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
  6. Global Immuno-oncology Drugs Market, By Disease Type, 2017 – 2030, (US$ Million)
    • Overview
      • Market Share Analysis, 2022 and 2030 (%)
      • Y-o-Y Growth Analysis, 2017 – 2030
      • Segment Trends
    •  Melanoma
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
    • Lung Cancer
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
    • Blood Cancer
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
    • Renal Cell Carcinoma
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
    • Prostate Cancer
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
    • Bladder Cancer
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
    • Others (Breast Cancer, Thyroid Cancer, etc.)
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
  7. Global Immuno-oncology Drugs Market, By Distribution Channel, 2017 – 2030, (US$ Million)
    • Overview
      • Market Share Analysis, 2022 and 2030 (%)
      • Y-o-Y Growth Analysis, 2017 – 2030
      • Segment Trends
    •  Hospital Pharmacies
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
    • Retail Pharmacies
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
    • Online Pharmacies
      • Overview
      • Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
  8. Global Immuno-oncology Drugs Market, By Region, 2017 – 2030, (US$ Million)
    • Introduction
      • Market Share Analysis, By Region, 2022 and 2030 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017–2030
      • Regional Trends
    • North America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
        • U.S.
        • Canada
    • Latin America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Middle East
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Technology, 2017 - Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
      • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million)
        • North Africa
        • Central Africa
        • South Africa
  9. Competitive Landscape
    • AbbVie Inc.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • AstraZeneca
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Bristol-Myers Squibb Company
      • Company Highlight
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Dendreon Pharmaceuticals LLC.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Hoffmann-La Roche Ltd.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Merck & Co., Inc.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Novartis AG
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Pfizer Inc.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Sanofi
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Ferring B.V.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Enzo Biochem Inc.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Celldex Therapeutics
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Atara Biotherapeutics, Inc.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Apexigen
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • BioNTech SE
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Blueprint Medicines Corporation
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Regeneron Pharmaceuticals Inc.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • CytomX Therapeutics, Inc.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Agenus Inc.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Betta Pharmaceuticals Co., Ltd.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • CStone Pharmaceuticals
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Amgen Inc.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • MediMergent, LLC
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Gilead Sciences, Inc.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • ONKO-INNATE
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
  10. Section
    • Research Methodology
    • About Us

*Browse 36 market data tables and 37 figures on "Global Immuno-oncology Drugs Market” - forecast to 2030

View Our Licence Options

  • Need a Custom Report?

    We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

    Customize Now
  • Want to Buy a Report but have a Limited Budget?

    We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail

    Request Discount
Logo

Reliability and Reputation

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo